Market closedNon-fractional

Prelude Therapeutics/PRLD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Prelude Therapeutics

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Ticker

PRLD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Wilmington, United States

Employees

128

PRLD Metrics

BasicAdvanced
$198M
Market cap
-
P/E ratio
-$1.87
EPS
1.55
Beta
-
Dividend rate
$198M
1.55
11.64
11.445
7.332
8.371
-38.59%
-65.04%
0.94
0.94
-2.171
-21.81%
-14.10%

What the Analysts think about PRLD

Analyst Ratings

Majority rating from 4 analysts.
Hold

PRLD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$31M
-4.85%
Profit margin
0.00%
NaN%

PRLD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.40%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.54
-$0.45
-$0.46
-$0.42
-
Expected
-$0.63
-$0.58
-$0.49
-$0.49
-$0.42
Surprise
-14.74%
-22.72%
-6.12%
-13.40%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Prelude Therapeutics stock?

Prelude Therapeutics (PRLD) has a market cap of $198M as of July 06, 2024.

What is the P/E ratio for Prelude Therapeutics stock?

The price to earnings (P/E) ratio for Prelude Therapeutics (PRLD) stock is 0 as of July 06, 2024.

Does Prelude Therapeutics stock pay dividends?

No, Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Prelude Therapeutics dividend payment date?

Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders.

What is the beta indicator for Prelude Therapeutics?

Prelude Therapeutics (PRLD) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Prelude Therapeutics stock

Buy or sell Prelude Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing